Creabilis Raises €15M in Series B Fundraising Round

05-Oct-2011 - Luxembourg

Creabilis SA has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company’s first-in-class treatments, including its lead product CT327 to the end of phase II.

CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis’ Low Systemic Exposure (LSE) technology. Positive efficacy of CT327 has been seen in two Phase IIa studies, in both psoriasis and atopic dermatitis, in which CT327 was well tolerated and demonstrated a good safety profile. CT327 is also in development for the treatment of pain, with proof-of-concept trials currently underway.

The company’s pipeline also includes CT637, a new approach to the treatment of significant inflammatory and autoimmune conditions and CT340, a potent TrkA kinase inhibitor that has therapeutic potential in a broad range of inflammatory conditions. CT637 and CT340 are anticipated to reach Investigational New Drug application (IND) stage of development in early 2012.

Dr Eliot Forster CEO of Creabilis said: “This new funding reflects the medical importance and significant commercial potential of our drugs pipeline. In Abbott Biotech Ventures, we have added another leading life science investor into the Company. Their involvement, and the ongoing support of our existing investors, demonstrates their confidence in the Company and in our ability to drive our projects forward.”

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Biocitech life science park boosts scientific score in 2008 - Biocitech residents further improve performance with 34 patents applied for, six new proofs of concept, seven pre-clinical trials and two clinical trials under way, 18 major scientific advances and a wide range of publications and scientific presentations

Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome

Intercell announces start of pivotal Phase II/III study in India for vaccine to protect children from Japanese Encephalitis

Quotient Clinical and Bend Research Announce Collaboration To Accelerate Advancement of New Medicines

Taking aim at skin bacteria - Enzyme treatment of skin samples improves microbiome analysis

Taking aim at skin bacteria - Enzyme treatment of skin samples improves microbiome analysis

SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD

SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD

Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus

Ion channel VRAC enhances immune response against viruses - New strategies against DNA viruses and cancer

Ion channel VRAC enhances immune response against viruses - New strategies against DNA viruses and cancer

Selvita Signs a Drug Discovery Services Contract With Rottapharm Madaus

Novel gene drives development of different types of ovarian cancer

Discovery of 100 million-year-old regions of DNA shows short cut to crop science advances

Traditional_Chinese_medicine